and generate anti-cancer effects on both 5637 and T24 cell lines. The device we build not only can inhibit proliferation but also can induce apoptosis and suppress migration of the bladder cancer cell lines 5637 and T24. Conclusions: The Tet-inducible small hairpin RNAs may provide a novel strategy for the treatment of human bladder cancer in the future.
AB128. Inhibiting cell migration and cell invasion by silencing the transcription factor ETS-1 in human bladder cancer Yuchen Liu, Li Liu, Weiren Huang, Zhiming Cai Shenzhen 2nd Hospital, Shenzhen 518029, China Objective: ETS-1, one of the members of the ETS gene family, is an important transcription factor that plays key role in the regulation of physiological processes in normal cells and in tumors. In this study, we aimed to investigate the relationship between the transcription factor ETS-1 and malignant phenotypes of bladder cancer. Methods: The expression pattern of ETS-1 was determined in bladder cancer tissues using qRT-PCR. Vectors expressing ETS-1 shRNA and ETS-1 protein were constructed in vitro and transfected into the human bladder cancer T24 and 5637 cells. Results: ETS-1 was up-regulated in human bladder cancer tissue compared to paired normal bladder tissue. Our results showed that the transcription factor ETS-1 could promote cell migration and cell invasion in human bladder cancer, without affecting cell proliferation and immortalization. Conclusions: ETS-1 plays oncogenic roles through inducing cell migration and invasion in human bladder cancer, and it can be used as a therapeutic target for treating human bladder cancer. Objective: To compare the clinical effects and surgical complications of different urinary diversion in the patients who underwent radical cystectomy. Methods: Retrospective analysis clinical data, surgical complications of short and long-term of 21 patients with radical cystectomy (11 with orthotopic sigmoid neobladder, 2 with orthotopic ileal neobladder, 6 with ureterocutaneostomy and 2 with sigma rectum pouch) in our hospital during the past 10 years. Results: Follow up had been made in 6-120 months, and all patients recovered smoothly and there was no tumor recurrence. After 6 month of the operation, no hydronephrosis was found in all cases. There were no significant differences in operation time, median blood loss and hospitalization between orthotopic sigmoid neobladder group and orthotopic ileal neobladder group (P>0.05). And there were significant difference in operation time, median
